Respiratory tract infections Infections and Infestations
Conditions
Interventions
The participants will be contacted approximately 30 days after the start of the treatment to conduct a telephone interview lasting approximately 10 minutes. They will be asked about any persisting com
Sponsors
BioMérieux (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, age >18 2. Lower respiratory tract infection (at least one respiratory symptom [cough, sputum production, dyspnea, tachypnea, pleuritic pain]) PLUS 3. One of the following auscultatory finding or sign of infection: 3.1. Core body temperature >38°C or 10 g/L or <4 g/L cells
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of antibiotic treatment All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adherence to procalcitonin algorithm 2. Adverse medical outcomes (complications, mortality, relapse, intensive care unit [ICU] admission) 3. Antibiotic side effects 4. Length of hospital stay 5. Differences between procalcitonin (PCT) levels measured by KRYPTOR® and VIDAS® All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment. | — |
Countries
France, Switzerland
Outcome results
None listed